UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended ~~September 30, 2022.~~March 31, 2023

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

Commission File Number: 333-82900

ThermoGenesis Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State of incorporation)

94-3018487

(I.R.S. Employer Identification No.)

2711 Citrus Road

Rancho Cordova, California 95742

(Address of principal executive offices) (Zip Code)

(916) 858-5100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $.001 par value		THMO		Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒

Emerging growth company ☐

~~Table of Contents~~

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

	Class		Outstanding at ~~November 8, 2022~~May 12, 2023
	Common stock, $.001 par value		~~45,997,792~~1,904,298

Table of Contents

ThermoGenesis Holdings, Inc.

INDEX

		Page Number
PART I	FINANCIAL INFORMATION

ITEM 1.	Financial Statements	1

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	20 18

~~ITEM 4.~~ ~~Controls and Procedures~~	20

~~PART II~~ ITEM 4.	~~OTHER INFORMATION~~Controls and Procedures	18

PART II	OTHER INFORMATION

ITEM 1.	Legal Proceedings	2119
ITEM 1A.	Risk Factors	2119
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2119
ITEM 3.	Defaults upon Senior Securities	2119
ITEM 4.	Mine Safety Disclosure	2119
ITEM 5.	Other Information	2119
ITEM 6.	Exhibits	2220

Signatures		23 21

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ThermoGenesis Holdings, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30, 2022			December 31, 2021			March 31, 2023			December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents	$	3,903,000		$	7,280,000		$	5,854,000		$	4,177,000
Accounts receivable, net of allowance for doubtful accounts of $149,000 ($156,000 at December 31, 2021)		2,056,000			733,000
Accounts receivable, net of allowance for doubtful accounts of $4,000 ($149,000 at December 31, 2022)								955,000			1,865,000
Inventories		4,912,000			5,373,000			3,426,000			3,334,000
Prepaid expenses and other current assets		612,000			1,578,000			734,000			1,508,000
Total current assets		11,483,000			14,964,000			10,969,000			10,884,000

Inventories non-current, net		930,000			1,709,000
Inventories, non-current								778,000			1,003,000
Equipment and leasehold improvements, net		1,271,000			1,261,000			1,931,000			1,254,000
Right-of-use operating lease assets, net		426,000			571,000			315,000			372,000
Right-of-use operating lease assets – related party, net		3,653,000			--			3,443,000			3,550,000
Goodwill		781,000			781,000			781,000			781,000
Other intangible assets, net		1,294,000			1,318,000
Intangible assets, net								1,278,000			1,286,000
Other assets		255,000			48,000			256,000			256,000
Total assets	$	20,093,000		$	20,652,000		$	19,751,000		$	19,386,000

LIABILITIES AND EQUITY
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,007,000		$	1,280,000		$	934,000		$	820,000
Accrued payroll and related expenses		493,000			348,000			445,000			399,000
Deferred revenue – short-term		841,000			719,000			729,000			782,000
Convertible promissory note – related party		5,133,000			--			6,499,000			5,777,000
Interest payable – related party		1,099,000			2,231,000			111,000			1,492,000
Convertible promissory note, net		1,000,000			813,000			423,000			962,000
Other current liabilities		1,395,000			957,000			1,330,000			1,277,000
Total current liabilities		10,968,000			6,348,000			10,471,000			11,509,000

Convertible promissory note – related party, net		--			9,245,000
Operating lease obligations – long-term		205,000			398,000			54,000			131,000
Operating lease obligations – related party – long-term		3,622,000			--			3,361,000			3,495,000
Deferred revenue – long-term		1,014,000			1,244,000			835,000			911,000
Other noncurrent liabilities		18,000			20,000			18,000			17,000
Total liabilities		15,827,000			17,255,000			14,739,000			16,063,000

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding		--			--			-			-

Common stock, $0.001 par value; 350,000,000 shares authorized; 31,321,362 issued and outstanding (11,911,784 at December 31, 2021)		31,000			12,000
Common stock, $0.001 par value; 350,000,000 shares authorized; 1,535,869 issued and outstanding (1,037,138 at December 31, 2022)								2,000			1,000
Additional paid in capital		267,731,000			268,447,000			277,253,000			270,377,000
Accumulated deficit		(262,761,000	)		(264,662,000	)		(271,279,000	)		(266,193,000	)
Accumulated other comprehensive loss		98,000			31,000			105,000			111,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity		5,099,000			3,828,000			6,081,000			4,296,000

Noncontrolling interests		(833,000	)		(431,000	)		(1,069,000	)		(973,000	)
Total equity		4,266,000			3,397,000			5,012,000			3,323,000
Total liabilities and equity	$	20,093,000		$	20,652,000		$	19,751,000		$	19,386,000

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2022			2021			2022			2021			2023			2022

Net revenues	$	2,115,000		$	3,158,000		$	7,807,000		$	6,876,000		$	2,572,000		$	2,663,000
Cost of revenues		1,678,000			2,043,000			5,491,000			4,067,000			1,467,000			1,723,000

Gross profit		437,000			1,115,000			2,316,000			2,809,000			1,105,000			940,000

Expenses:

Selling, general and administrative		1,982,000			1,677,000			5,665,000			7,171,000			1,844,000			1,693,000
Research and development		470,000			543,000			1,317,000			1,544,000			306,000			456,000

Total operating expenses		2,452,000			2,220,000			6,982,000			8,715,000			2,150,000			2,149,000

Loss from operations		(2,015,000	)		(1,105,000	)		(4,666,000	)		(5,906,000	)		(1,045,000	)		(1,209,000	)

Other expenses:
Other income (expenses):
Interest expense		(1,391,000	)		(1,530,000	)		(3,572,000	)		(4,573,000	)		(3,903,000	)		(823,000	)
Gain on extinguishment of debt		--			--			--			652,000
Other income/(expense)		3,000			843,000			(1,000	)		833,000

Total other expense		(1,388,000	)		(687,000	)		(3,573,000	)		(3,088,000	)
Loss on retirement of debt														(239,000	)		-
Other income (expenses)														5,000			(4,000	)
Total other expenses														(4,137,000	)		(827,000	)

Net loss		(3,403,000	)		(1,792,000	)		(8,239,000	)		(8,994,000	)		(5,182,000	)		(2,036,000	)

Loss attributable to noncontrolling interests		(163,000	)		(18,000	)		(402,000	)		(269,000	)		(96,000	)		(126,000	)
Net loss attributable to common stockholders	$	(3,240,000	)	$	(1,774,000	)	$	(7,837,000	)	$	(8,725,000	)	$	(5,086,000	)	$	(1,910,000	)

COMPREHENSIVE LOSS
Net loss	$	(3,403,000	)	$	(1,792,000	)	$	(8,239,000	)	$	(8,994,000	)	$	(5,182,000	)	$	(2,036,000	)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)		22,000			(1,000	)		67,000			12,000			(6,000	)		14,000
Comprehensive loss		(3,381,000	)		(1,793,000	)		(8,172,000	)		(8,982,000	)		(5,188,000	)		(2,022,000	)
Comprehensive loss attributable to noncontrolling interests		(163,000	)		(18,000	)		(402,000	)		(269,000	)		(96,000	)		(126,000	)
Comprehensive loss attributable to common stockholders	$	(3,218,000	)	$	(1,775,000	)	$	(7,770,000	)	$	(8,713,000	)	$	(5,092,000	)	$	(1,896,000	)

Per share data:

Basic and diluted net loss per common share	$	(0.10	)	$	(0.15	)	$	(0.41	)	$	(0.74	)	$	(4.07	)	$	(6.63	)

Weighted average common shares outstanding – basic and diluted		31,265,797			11,911,784			19,075,331			11,757,211
Weighted average common shares outstanding basicand diluted														1,249,576			288,003

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Equity

For the Three ~~and Nine~~ Months Ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~

(Unaudited)

	Shares		Common Stock		Paid in Capital in Excess of Par			Accumulated Deficit			AOCL*		Non- Controlling Interests			Total Equity			Shares		Common Stock		Paid in Capital in Excess of Par		Accumulated Deficit			AOCL*			Non-Controlling Interests			Total Equity
Balance at January 1, 2022		11,911,784	$	12,000	$	268,447,000		$	(264,662,000	)	$	31,000	$	(431,000	)	$	3,397,000
Balance at January 1, 2023																				1,037,138	$	1,000	$	270,377,000	$	(266,193,000	)	$	111,000		$	(973,000	)	$	3,323,000

Adoption of ASU 2020-06		--		--		(10,681,000	)		9,739,000			--		--			(942,000	)
Stock-based compensation expense		--		--		42,000			--			--		--			42,000			-		-		10,000		-			-			-			10,000
Issuance of common stock via at-the-market offering, net		918,093		1,000		593,000			--			--		--			594,000
Related party convertible note price reset						213,000											213,000			-		-		3,160,000		-			-			-			3,160,000
Convertible note price reset																				-		-		43,000		-			-			-			43,000
Conversion of note payable to common stock																				215,000		1,000		602,000		-			-			-			603,000
Sale of common stock and warrants, net																				125,000		-		2,640,000		-			-			-			2,640,000
Exercise of warrants																				158,731		-		421,000		-			-			-			421,000
Foreign currency translation gain		--		--		--			--			14,000		--			14,000			-		-		-		-			(6,000	)		-			(6,000	)
Net loss		--		--		--			(1,910,000	)		--		(126,000	)		(2,036,000	)		-		-		-		(5,086,000	)		-			(96,000	)		(5,182,000	)
Balance at March 31, 2022		12,829,877	$	13,000	$	258,614,000		$	(256,833,000	)	$	45,000	$	(557,000	)	$	1,282,000

Stock-based compensation expense		--		--		72,000			--			--		--			72,000
Issuance of common stock via at-the-market offering, net		4,397,329		4,000		1,446,000			--			--		--			1,450,000
Related party convertible note price reset		--		--		2,475,000			--			--		--			2,475,000
Conversion of related party note payable to common stock		10,552,234		11,000		2,989,000			--			--		--			3,000,000
Foreign currency translation gain		--		--		--			--			31,000		--			31,000
Net loss		--		--		--			(2,688,000	)		--		(113,000	)		(2,801,000	)
Balance at June 30, 2022		27,779,440		28,000		265,596,000			(259,521,000	)		76,000		(670,000	)		5,509,000

Stock-based compensation expense		--		--		70,000			--			--		--			70,000
Issuance of common stock via at-the-market offering, net		3,541,922		3,000		990,000			--			--		--			993,000
Related party convertible note price reset		--		--		1,075,000			--			--		--			1,075,000
Foreign currency translation gain		--		--		--			--			22,000		--			22,000
Net loss		--		--		--			(3,240,000	)		--		(163,000	)		(3,403,000	)
Balance at September 30, 2022		31,321,362	$	31,000	$	267,731,000		$	(262,761,000	)	$	98,000	$	(833,000	)	$	4,266,000
Balance at March 31, 2023																				1,535,869	$	2,000	$	277,253,000	$	(271,279,000	)	$	105,000		$	(1,069,000	)	$	5,012,000

~~Table of Contents~~

	Shares		Common Stock		Paid in Capital in Excess of Par		Accumulated Deficit			AOCL*			Non- Controlling Interests			Total Equity			Shares		Common Stock		Paid in Capital in Excess of Par			Accumulated Deficit			AOCL*		Non-Controlling Interests			Total Equity
Balance at January 1, 2021		8,934,952	$	9,000	$	259,058,000	$	(253,283,000	)	$	16,000		$	70,000		$	5,870,000
Balance at January 1, 2022																				279,629	$	-	$	268,459,000		$	(264,662,000	)	$	31,000	$	(431,000	)	$	3,397,000

Adoption of ASU 2020-06																				-		-		(10,681,000	)		9,739,000			-		-			(942,000	)
Stock-based compensation expense		--		--		258,000		--			--			--			258,000			-		-		42,000			-			-		-			42,000
Issuance of common stock via at-the-market offering, net		2,976,832		3,000		6,829,000		--			--			--			6,832,000
Issuance of common stock via at- the-market offering, net																				20,407		-		594,000			-			-		-			594,000
Related party convertible note price reset																								213,000											213,000
Foreign currency translation gain		--		--		--		--			1,000			--			1,000			-		-		-			-			14,000		-			14,000
Net loss		--		--		--		(2,413,000	)		--			(118,000	)		(2,531,000	)		-		-		-			(1,910,000	)		-		(126,000	)		(2,036,000	)
Balance at March 31, 2021		11,911,784	$	12,000	$	266,145,000	$	(255,696,000	)	$	17,000		$	(48,000	)	$	10,430,000

Stock-based compensation expense		--		--		2,099,000		--			--			--			2,099,000
Foreign currency translation gain		--		--		--		--			12,000			--			12,000
Net loss		--		--		--		(4,539,000	)		--			(133,000	)		(4,672,000	)
Balance at June 30, 2021		11,911,784	$	12,000	$	268,244,000	$	(260,235,000	)	$	29,000		$	(181,000	)	$	7,869,000

Stock-based compensation expense		--		--		92,000		--			--			--			92,000
Foreign currency translation gain		--		--		--		--			(1,000	)		--			(1,000	)
Net loss		--		--		--		(1,774,000	)		--			(18,000	)		(1,792,000	)
Balance at September 30, 2021		11,911,784	$	12,000	$	268,336,000	$	(262,009,000	)	$	28,000		$	(199,000	)	$	6,168,000
Balance at March 31, 2022																				300,036	$	-	$	258,627,000		$	(256,833,000	)	$	45,000	$	(557,000	)	$	1,282,000

* Accumulated other comprehensive loss.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended September 30,						Three Months Ended March 31,
	2022			2021			2023			2022
Cash flows from operating activities:
Net loss	$	(8,239,000	)	$	(8,994,000	)	$	(5,182,000	)	$	(2,036,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		666,000			477,000			267,000			150,000
Stock based compensation expense		184,000			2,449,000
Amortization of debt discount, net		1,897,000			2,723,000
Stock-based compensation expense								10,000			42,000
Amortization of debt discount/premium, net								3,472,000			213,000
Loss on extinguishment of debt								239,000			-
Reserve for excess and slow-moving inventories		654,000			336,000			70,000			374,000
Gain on extinguishment of debt		--			(652,000	)
Net change in operating assets and liabilities:
Accounts receivable		(1,323,000	)		(1,190,000	)		271,000			(1,442,000	)
Inventories		582,000			(742,000	)		58,000			(383,000	)
Prepaid expenses and other assets		757,000			(260,000	)		778,000			103,000
Accounts payable		(210,000	)		145,000			748,000			599,000
Interest payable – related party		(1,132,000	)		(413,000	)
Interest payable - related party								(1,103,000	)		(2,078,000	)
Accrued payroll and related expenses		145,000			111,000			45,000			107,000
Deferred revenue – short-term		122,000			334,000
Deferred revenue – short term								(53,000	)		441,000
Other current liabilities		446,000			(271,000	)		53,000			(112,000	)
Long-term deferred revenue and other noncurrent liabilities		(650,000	)		(347,000	)		(288,000	)		(137,000	)

Net cash used in operating activities		(6,101,000	)		(6,294,000	)		(615,000	)		(4,159,000	)

Cash flows from investing activities:
Capital expenditures		(308,000	)		(64,000	)		(771,000	)		(65,000	)

Net cash used in investing activities		(308,000	)		(64,000	)		(771,000	)		(65,000	)

Cash flows from financing activities:

Proceeds from issuance of common stock, net of expenses		3,037,000			6,832,000
Proceeds from sale of common stock and warrants, net								2,640,000			594,000
Proceeds from exercise of warrants								421,000			-

Net cash provided by financing activities		3,037,000			6,832,000			3,061,000			594,000

Effects of foreign currency rate changes on cash and cash equivalents		(5,000	)		(1,000	)		-			2,000
Net increase (decrease) in cash, cash equivalents and restricted cash		(3,377,000	)		473,000			1,675,000			(3,628,000	)

Cash, cash equivalents and restricted cash at beginning of period		7,280,000			7,161,000			4,177,000			7,280,000
Cash, cash equivalents and restricted cash at end of period	$	3,903,000		$	7,634,000		$	5,852,000		$	3,652,000

Supplemental disclosures of cash flow information:
Cash paid for interest							$	140,000		$	60,000
Cash paid for related party interest	$	2,628,000		$	2,082,000		$	1,492,000		$	2,628,000
Cash paid for interest	$	180,000		$	180,000
Right-to-use asset acquired under operating lease	$	3,863,000			--
Related party promissory note converted to common stock	$	3,000,000			--
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note							$	1,239,000			-
Convertible note price reset							$	43,000			-
Related party convertible note price reset	$	3,763,000			--		$	3,160,000		$	213,000
Transfer of inventory to fixed assets		--		$	181,000
Promissory note converted to common stock							$	603,000			-

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

ThermoGenesis Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.	Description of Business

Overview

ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Since the 1990’s, ThermoGenesis Holdings has been a pioneer in, and a leading provider of automated systems that isolate, purify and cryogenically store units of hematopoietic stem and progenitor cells for the cord blood banking industry. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA. Our common stock is traded on the Nasdaq Capital Market exchange under the ticker symbol “THMO”.

Medical Device Products for Automated Cell Processing

The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and the CAR-TXpress™ platform for large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements.

~~Planned~~ CDMO Business

~~In March 2022, our Board of Directors approved the planned expansion of the Company’s~~The Company is expanding its business to include contract development and manufacturing services for cell and cell-based gene therapies. The Company ~~plans to develop and build-out~~is in the process of building out the capabilities to become a world-class Contract Development and Manufacturing Organization (“CDMO”) for cell and cell-based gene therapies by partnering with Boyalife Genomics Tianjin Ltd., a China-based CDMO (“Boyalife Genomics”), to in-license certain know-how and other intellectual property from Boyalife Genomics, and by leasing and buildingtherapies. The Company is rolling out a ~~cell manufacturing~~new facility in the Sacramento ~~California.~~metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy companies. The ReadyStart Suites are located in a 35,500+ square foot cGMP facility that will meet the highest scientific, quality, and regulatory requirements. We ~~intend~~expect the CDMO facility to ~~leverage our existing technology and combine it with the in-licensed technologies to develop~~be completed in 2023.

Reverse Stock Split

On December 22, 2022, we effected a ~~proprietary manufacturing platform~~one (1) for ~~cell manufacturing activities and other cell manufacturing solutions for clients with therapeutic candidates in various stages of development. We are targeting the launch~~forty-five (45) reverse stock split of our ~~CDMO services~~issued and outstanding common stock. All historical share amounts disclosed in this quarterly report on Form 10-Q have been retroactively restated to ~~customers in 2023.~~reflect the reverse split and subsequent share exchange. No fractional shares were issued as a result of the reverse stock split, as fractional shares of common stock were rounded up to the nearest whole share.

2.	Going Concern

The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report.

Table of Contents

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

~~Table of Contents~~

3.	Summary of Significant Accounting Polices

There have been no material changes in the Company’s significant accounting policies to those disclosed in the ~~2021~~2022 Annual Report.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance.

Operating results for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023 are not necessarily indicative of the results that may be expected for the Company’s fiscal year ~~ended~~ending December 31, ~~2022.~~2023. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings’ Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022.

Principles of Consolidation

The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.

The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.

Table of Contents

Recently Adopted Accounting Standards

On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2020-06 “Debt-Debt with Conversion and Other Options (“Subtopic 470-20”) and Derivatives and Hedging-Contracts in Entity’s Own Equity (“Subtopic 815-40”): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” using the modified retrospective method. ASU 2020-06 provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. The Company recognized a cumulative effect of $9,739,000 of initially applying the ASU as an adjustment to the January 1, 2022 opening balance of accumulated deficit. Due to the recombination of the equity conversion component of our convertible debt outstanding, the 2022 opening balance of additional paid in capital was reduced by $10,681,000 and the debt discounts of the convertible promissory notes were reduced $942,000.

~~Table~~

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (“Topic 326”). The ASU introduced a new accounting model, the Current Expected Credit Losses model (“CECL”), which requiresearlier recognition of ~~Contents~~

credit losses and additional disclosures related to credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial asset is originated or acquired. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2022, including interim reporting periods within those annual reporting periods. The Company adopted the standard effective January 1, 2023. Based on the composition of the Company’s trade receivables and unbilled revenue, and expected future losses, the adoption of ASU 2016-13 did not have a material impact on its condensed consolidated financial statements.

4.	Related Party Transactions

Convertible Promissory Note and Revolving Credit Agreement

In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Group (USA), Inc. (the “Lender”), which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to the maturity date. On March 6, 2023, the Company entered into an Amendment No. 2 (the “Amendment to the Note”) to its Second Amended and Restated Convertible Promissory Note with Boyalife Group Inc. (the “Note”), and an Amendment No. 3 to its First Amended and Restated Revolving Credit Agreement with Boyalife Group Inc. The Amendment to the Note amended and extended the maturity date of the Note from March 6, 2023 to December 31, 2023 (the “Maturity Date”). , and added to the principal balance of the Note all accrued and unpaid interest at the time of the extension, resulting in an outstanding principal balance of $7,278,000.

The Company performed a debt extinguishment vs. modification ~~analysis. The~~ analysis on the Amendment to the Note and determined that the ~~extension~~amendment would be considered an extinguishment, ~~from an accounting standpoint,~~ due to ~~the change in~~an increase of more than 10% to the value of the embedded conversion option. ~~In June 2022,~~However, no gain or loss was recorded in the ~~Lender converted a total~~condensed consolidated statements of ~~$3,000,000~~operations and comprehensive loss for the quarter ended March 31, 2023 as it was determined that the fair value of the ~~outstanding balance of~~Amendment to the ~~convertible note into 10,552,234 shares of our common stock. As of September 30, 2022~~Note and ~~December 31, 2021,~~accrued interest was $7,278,000 both before and after the ~~outstanding principle balance of the Loan was $7,000,000 and $10,000,000, respectively.~~extension.

The Credit Agreement and the ~~Convertible Promissory~~ Note, ~~issued thereunder,~~ as amended ~~(the “Note”)~~ provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Loan can be prepaid in whole or in part by the Company at any time without penalty.

Table of Contents

The following summarizes the Note:

Maturity
Date

Stated
Interest
Rate

Conversion
Price

Face
Value

Debt
Discount

Carrying
Value

September 30, 2022
3/6/2023 22 % $ 0.21 $ 7,000,000 $ (1,867,000 ) $ 5,133,000
December 31, 2021
3/6/2022 22 % $ 1.80 $ 10,000,000 $ (755,000 ) $ 9,245,000

Maturity

Date

Stated

Interest

Rate

Conversion

Price

Face

Value

Debt

Discount

Carrying

Value

March 31, 2023

12/31/23

2.65

7,278,000

(779,000

)

6,499,000

December 31, 2022

12/31/23

6.30

7,000,000

(1,223,000

)

5,777,000

The Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock or issues convertible debt at a lower price per share. In ~~2022,~~2023, the ~~anti-dilution~~down-round provision was triggered ~~three~~two times, as noted below:

In ~~February 2022,~~January 2023, when the conversion price of the Note was at ~~$1.80~~$6.30 per share, the Company ~~sold shares of common stock at $0.64 per share. This resulted~~amended a previously outstanding convertible note, resulting in a triggering event lowering the conversion price of the Note to ~~that value.~~$2.87. The Company determined that it created an incremental value of ~~$213,000~~$2,350,000 which was treated as a ~~debt~~ discount to the carrying amount of the Note and amortized over ~~the~~its remaining ~~term of the Note.~~term.

In ~~June 2022,~~March 2023, the Company sold shares of common stock and warrants at ~~$0.28~~$2.65 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of ~~$2,475,000~~$810,000 which was treated as a ~~debt~~ discount to the carrying amount of the Note and will be amortized over ~~the~~its remaining ~~term of the Note.~~term.

In July 2022, the Company modified a convertible debt agreement, lowering the conversion price of the debt to $0.21 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $1,075,000 which was treated as a debt discount and will be amortized over the remaining term of the Note.

~~Table of Contents~~

A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option at each triggering event, with the following inputs:

	February 2022			June 2022			July 2022			January 2023			March 2023
Conversion price before	$	1.80		$	0.64		$	0.28		$	6.30		$	2.87
Conversion price after	$	0.64		$	0.28		$	0.21		$	2.87		$	2.65
Term (years)		0.02			0.69			0.61			0.09			0.78
Volatility		39.53	%		85.6	%		99.5	%		167	%		168.9	%
Dividend rate		0	%		0	%		0	%		0	%		0	%
Risk free rate		1.97	%		3.2	%		2.8	%		4.46	%		4.20	%

The Company amortized ~~$940,000~~$3,604,000 and ~~$1,897,000~~$213,000 of debt discount related to triggering events to interest expense for the three ~~and nine~~ months ended ~~September 30, 2022. The amortization included $742,000, which related to accelerated amortization for the portion of the Note that was converted in June 2022.~~March 31, 2023 and 2022, respectively. In addition to the amortization, the Company also recorded interest expense of ~~$394,000~~$389,000 and ~~$1,496,000~~$550,000 for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and $562,000 and $1,668,000 for the three and nine months ended September 30, 2021.~~respectively. The interest payable balance as of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 was ~~$1,099,000~~$111,000 and ~~$2,231,000,~~$1,492,000, respectively.

Boyalife Genomics

On March 24, 2022, the Company entered into a License and Technology Access Agreement with Boyalife Genomics Tianjin Ltd. (“Boyalife Genomics”), a China-based CDMO and an affiliate of ThermoGenesis’ Chairman and Chief Executive Officer, Chris Xu, Ph.D. The agreement provides for a U.S. license to certain existing and future know-how and other intellectual property relating to cell manufacturing and related processes. The Company plans to develop and operate the CDMO cell therapy manufacturing business through a newly formed division named TG Biosynthesis.

Table of Contents

Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one or more of Boyalife Genomics’ granted U.S. patents and a royalty of 5.0% of other products and services covered by other licensed intellectual property. In the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, no sales were recorded under the license agreement and no royalty payments were made to Boyalife Genomics.

5.	Related Party Lease

Z3 Investment

On March 24, 2022, the Company entered into a five year Lease Agreement with Z3 Investment LLC, an affiliate owned by the Company’s CEO and Chairman of the ~~Company’s Chairman~~Board and ~~CEO,~~it’s COO who is also a Board Member, beginning April 1, 2022, for approximately 35,000 square feet of laboratory and office space in Rancho Cordova, California. Under the terms of the agreement, monthly rent is ~~$46,000 per month for the first six months, then increasing to~~ $104,000 per month (with a 4% annual increase) thereafter. Additionally, the Company will pay all operating expenses as they become due estimated to be approximately $5,000 per month and will be expensed in the period incurred. The Company has the option to renew the lease for two 5-year periods. Additionally, the Company has the ability to opt out of the lease after one year if the CDMO facility is unable to be constructed as planned.

~~The Company performed an analysis of the lease and determined it to be an operating lease. A right-of-use asset and lease obligation were recorded at inception of the lease.~~

~~Table of Contents~~

Operating Lease

Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. We recognize the expense for this lease on a straight-line basis over the lease term.

The following summarizes the Company’s operating lease:

	September 30, 2022			March 31, 2023			December 31, 2022
Right-of-use operating lease assets – related party, net	$	3,653,000		$	3,443,000		$	3,550,000
Current lease liability (included in other current liabilities)		397,000			470,000			433,000
Non-current lease liability – related party		3,622,000			3,361,000			3,495,000

Weighted average remaining lease term		5.00			4.5			4.8
Discount rate		22	%		22	%		22	%

Maturities of lease liabilities by year for our operating lease are as follows:

2022 (Remaining)	$	311,000
2023		1,256,000
2023 (Remaining)				$	945,000
2024		1,307,000			1,307,000
2025		1,359,000			1,359,000
2026		1,428,000			1,428,000
Thereafter		1,133,000			1,133,000
Total lease payments	$	6,794,000		$	6,172,000
Less: imputed interest		(2,775,000	)		(2,341,000	)
Present value of operating lease liabilities	$	4,019,000		$	3,831,000

Table of Contents

Statement of Cash Flows

Cash paid for amounts included in the measurement of operating lease liabilities was ~~$138,000 and $277,000~~$321,000 for the three ~~and nine~~ months ended ~~September 30, 2022, respectively.~~March 31, 2023.

6.	Convertible Promissory Note

July 2019 Note

On July 23, 2019, the Company entered into a private placement with ~~the Accredited Investor,~~Orbrex (USA) Co. Limited (“Orbrex”), pursuant to which the Company issued and sold to ~~such investor~~Orbrex an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at a rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on JulyOn January 31, ~~2022.~~

~~Table of Contents~~

~~On July 25, 2022,~~2023, the Company entered into ~~an amendment~~Amendment No. 3 to the July 2019 ~~Note, which~~Note. The amendment extended the maturity date ~~of the July 2019 Note to~~from January 31, 2023 to July 31, 2023 and ~~modified when interest is due from quarterly to January 31, 2023. The amendment also (i) deleted~~changed the market price-based conversion right, which previously allowed for the July 2019 Note to be converted at a conversion price of 90% of the Company’s stock price on the day of conversion (subject to a $0.50 floor); and (ii) changed to a fixed conversion price to ~~$0.21~~$2.87 per share, provided that in the event that the Company issues shares, options, warrants, or convertible securities, at an effective price per common share lower than $0.21, then the conversion price will be adjusted to such lower issuance price.share.

The Company performed a debt extinguishment vs. modification analysis on the amendment to the July 2019 Note and determined that the extension would be considered an extinguishment, due to an increase of more than 10% to the value of the embedded conversion option. ~~No gain or loss was recorded in the consolidated statement of operations for the quarter ended September 30, 2022 as it was~~The Company determined that the fair value of the July 2019 Note after the amendment was $1,239,000 representing a $239,000 increase in its fair value. The increase will be recorded as a premium to the July 2019 Note and amortized over the remaining term.

During the three months ended March 31, 2023, the holder of the July 2019 Note ~~and accrued interest was $1,020,000 both before and after~~converted $603,000 of the ~~extension.~~Note for 215,000 shares. The current outstanding balance of the Note is $397,000.

The following summarizes the July 2019 Note:

Maturity
Date

Stated
Interest Rate

Conversion
Price

Carrying
Value

September 30, 2022
1/31/2023
24 % $ 0.21 $ 1,000,000
December 31, 2021
7/31/2022
24 % $ 0.91 $ 813,000

Maturity

Date

Stated

Interest Rate

Conversion

Price

Face
Value

Debt
Discount

Debt
Premium

Carrying

Value

March 31, 2023

7/31/2023

2.65

397,000

(40,000

)

66,000

423,000

December 31, 2022

7/31/2023

6.30

1,000,000

(38,000

)

962,000

The Note includes a down-round anti-dilution provision that lowers its conversion price if the Company sells shares of common stock or issues convertible debt at a lower price per share. In 2023, the anti-dilution provision was triggered, as noted below:

In March 2023, the Company sold shares of common stock at $2.65 per share, resulting in a down round triggering event lowering the conversion price of the Note to that value. The triggering event created an incremental value of $43,000 which was treated as a discount to the carrying amount of the July 2019 Note and will be amortized over its remaining term.

Table of Contents

A Black-Scholes pricing model was utilized to determine the change in the before and after incremental value of the conversion option at each triggering event, with the following inputs:

	March 2023
Conversion price before	$	2.87
Conversion price after	$	2.65
Term (years)		0.36
Volatility		182	%
Dividend rate		0	%
Risk free rate		4.20	%

The Company recorded amortization ~~of debt discount on~~expense related to triggering events for the July 2019 Note of ~~$80,000 and $241,000~~$41,000 for the three ~~and nine~~ months ended ~~September 30, 2021.~~March 31, 2023. Additionally, amortization expense related to the debt premium for the July 2019 Note was $174,000 for the three months ended March 31, 2023. Interest expense related to the July 2019 Note was ~~$60,000~~$42,000 and ~~$180,000~~$60,000 for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021.~~respectively.

7.	Stockholders’ Equity

Common Stock

On March 15, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to issue and sell to the Investor in a private placement (the “Offering”) (i) 125,000 shares of its common stock, $0.001 par value (the “Common Shares”), (ii) 946,429 pre-funded warrants to purchase Common Shares at a purchase price of $2.80, and (iii) warrants to purchase up to an aggregate 1,071,429 Common Shares were issued (the “Underlying Shares”). The warrants have an exercise price of $2.65 per share and are exercisable immediately upon issuance and expire five and one-half years following the issuance for a total net proceeds of approximately $2.6 million, excluding legal and transaction fees of $360,000. The Offering closed on March 20, 2023.

In connection with the Offering, the Company entered into a Warrant Amendment Agreement (the "Warrant Amendment Agreement”), dated March 15, 2023, with the Investor, whereby the Company agreed to amend existing warrants, held by the Investor, to purchase up to an aggregate of 158,731 shares of common stock under the Warrant Amendment Agreement that were previously issued in October 2022. These warrants had an exercise price of $6.30 per share and pursuant to the Warrant Amendment Agreement, have been amended to reduce the exercise price to $2.65 per share effective upon the closing of the Offering. During the quarter ended March 31, 2023, 158,731 common warrants were exercised. The Company received approximately $421,000 from the exercises of the warrants.

The warrant repricing resulted in an immediate and incremental increase of approximately $50,000 in the estimated fair value of the common warrants issued in the Company’s October 2022 public offering. The common warrants were valued on the date of the warrant repricing using the Black-Scholes option pricing model based on the following assumptions:

	March 2023
Conversion price before	$	6.30
Conversion price after	$	2.65
Term (years)		4.9
Volatility		123	%
Dividend rate		0	%
Risk free rate		4.20	%

Table of Contents

On February 3, 2022, the Company entered into Amendment No. 2 to the At the Market Offering Agreement (the “Offering Agreement”) with H.C. Wainwright & Co., LLC to further increase the maximum aggregate offering price of shares of Common Stock that may be offered and sold from time to time under the Offering Agreement from $15,280,000 to $~~19,555,000~~,$19,555,000, which enables the Company to sell an additional $4,275,000 of shares after taking into account prior sales under the Offering Agreement (the “Additional Shares”). ~~After filing the Company’s 2021 Form 10-K in~~In March 2022, the total offering price was updated to $18,573,000 based on the shares that were currently available on Company’s existing Form S-3. The terms and conditions of the Offering Agreement otherwise remain unchanged. For the ~~nine months~~quarter ended ~~September 30,~~March 31, 2022, the Company sold a total of ~~8,857,344~~20,407 shares of common stock under the Offering Agreement for aggregate gross proceeds of ~~$3,293,000~~$681,000 at an average selling price of ~~$0.37~~$33.30 per share, resulting in net proceeds of approximately ~~$3,037,000~~$594,000 after deducting commissions and other transaction costs of approximately ~~$256,000.~~

~~Table of Contents~~

~~Equity Plans~~

On January 13, 2022, the Company’s stockholders approved an amendment of the Company’s Amended 2016 Equity Incentive Plan to increase the aggregate number of shares of the Company’s common stock that may be issued under the plan from 392,500 shares to 1,200,000 shares.$87,000.

Net Loss Per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares ~~outstanding.~~outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no vesting or other contingencies associated with them. There were 946,429 pre-funded warrants included in the quarter ended March 31, 2023 calculation. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at ~~September 30:~~March 31:

	2022		2021		2023		2022
Common stock equivalents of convertible promissory notes and accrued interest		43,612,759		7,071,241		2,946,525		157,139
Warrants – other		653,248		653,248		1,253,387		14,518
Stock options		287,081		366,595		6,400		8,147
Total		44,553,088		8,091,084		4,206,312		179,804

Warrants

A summary of warrant activity for the three months ended March 31, 2023 is as follows:

	Number of Shares			Weighted-Average Exercise Price Per Share		Weighted- Average Remaining Contract Term
Balance at December 31, 2022		340,689		$	19.40		1.90
Warrants granted		1,071,429
Pre-funded warrants granted		946,429
Warrants exercised		(158,731	)
Exercisable and Outstanding at March 31, 2023		2,199,816		$	3.84		2.56

Table of Contents

Revenue

The following table presents net sales by geographic ~~areas:~~areas for the three months ended March 31:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021		2023		2022
United States	$	1,535,000	$	1,517,000	$	4,973,000	$	3,558,000	$	1,372,000	$	1,958,000
China		364,000		1,357,000		1,570,000		1,445,000
Thailand		2,000		--		10,000		400,000
Singapore										404,000		-
Other		214,000		284,000		1,254,000		1,473,000		796,000		705,000
Total	$	2,115,000	$	3,158,000	$	7,807,000	$	6,876,000	$	2,572,000	$	2,663,000

The following tables summarize the revenues by product line and type:

	Three Months Ended September 30, 2022								Three Months Ended March 31, 2023
	Device Revenue		Service Revenue		Other Revenue		Total Revenue		Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,034,000	$	75,000	$	--	$	1,109,000	$	1,484,000	$	55,000	$	-	$	1,539,000
BioArchive		201,000		321,000		--		522,000		298,000		359,000		-		657,000
CAR-TXpress		190,000		44,000		72,000		306,000		35,000		40,000		71,000		146,000
Manual Disposables		150,000		--		--		150,000		207,000		-		-		207,000
Other		20,000		--		8,000		28,000		17,000		-		6,000		23,000
Total	$	1,595,000	$	440,000	$	80,000	$	2,115,000	$	2,041,000	$	454,000	$	77,000	$	2,572,000

~~Table of Contents~~

Nine Months Ended September 30, 2022

Device
Revenue

Service
Revenue

Other
Revenue

Total
Revenue

AXP
$ 4,668,000 $ 171,000 $ -- $ 4,839,000
BioArchive
694,000 924,000 -- 1,618,000
CAR-TXpress
551,000 146,000 214,000 911,000
Manual Disposables
357,000 -- -- 357,000
Other
59,000 -- 23,000 82,000
Total
$ 6,329,000 $ 1,241,000 $ 237,000 $ 7,807,000

Three Months Ended September 30, 2021

Device
Revenue

Service
Revenue

Other
Revenue

Total
Revenue

AXP
$ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000
BioArchive
221,000 297,000 -- 518,000
CAR-TXpress
160,000 31,000 71,000 262,000
Manual Disposables
55,000 -- -- 55,000
Other
9,000 -- 4,000 13,000
Total
$ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000

	Nine Months Ended September 30, 2021								Three Months Ended March 31, 2022
	Device Revenue		Service Revenue		Other Revenue		Total Revenue		Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	3,490,000	$	159,000	$	21,000	$	3,670,000	$	1,711,000	$	55,000	$	-	$	1,766,000
BioArchive		652,000		1,165,000		--		1,817,000		155,000		298,000		-		453,000
CAR-TXpress		702,000		89,000		214,000		1,005,000		199,000		43,000		71,000		313,000
Manual Disposables		300,000		--		--		300,000		105,000		-		-		105,000
Other		46,000		--		38,000		84,000		17,000		-		9,000		26,000
Total	$	5,190,000	$	1,413,000	$	273,000	$	6,876,000	$	2,187,000	$	396,000	$	80,000	$	2,663,000

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues ~~recognized during the three and nine months ended September 30, 2022~~ that were included in the beginning balance of deferred revenue at March 31, 2023 and December 31, 2022 were ~~$144,000~~$362,000 and ~~$620,000,~~$719,000, respectively. Short-term deferred revenues were ~~$841,000~~$729,000 and ~~$719,000~~$782,000 at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. Long-term deferred ~~revenue was $1,014,000~~revenues were $835,000 and ~~$1,244,000~~$911,000 at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively.

Table of Contents

Backlog of Remaining Customer Performance Obligations

The following table represents revenue expected to be recognized in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period:

	Remainder of 2022			2023			2024			2025			2026 and beyond			Total		Remainder of 2023		2024		2025		2026		2027 and beyond		Total
Service revenue	$	407,000	0.25	$	1,089,000	1	$	664,000	1	$	176,000	1	$	--	1	$	2,336,000
Service revenue0.750.750.750.750.7511111111111111111111																		$	961,000	$	659,000	$	244,000	$	-	$	-	$	1,864,000
Device revenue ⁽¹⁾		21,000	0.25		733,000	1		41,000	1		--	1		--	1		795,000		712,000		41,000		-		-		-		753,000
Exclusivity fee		71,000	0.25		286,000	1		286,000	1		286,000	1		190,000	1		1,119,000		214,000		286,000		286,000		190,000		-		976,000
Other		3,000	0.25		13,000	1		13,000	1		13,000	1		122,000	1		164,000		10,000		13,000		13,000		13,000		104,000		153,000
Total	$	502,000	0.25	$	2,121,000	1	$	1,004,000	1	$	475,000	1	$	312,000	1	$	4,414,000	$	1,897,000	$	999,000	$	543,000	$	203,000	$	104,000	$	3,746,000

(1)

Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

9.	Concentrations

The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable as follows:

~~Accounts Receivable~~

Accounts Receivable	March 31, 2023			December 31, 2022
Customer 1		20	%		15	%
Customer 2		16	%		-
Customer 3		1	%		27	%
Customer 4		-			29	%

September 30, 2022

December 31, 2021

Customer 1
49 % --
%
Customer 2
15 % 28
%
Customer 3
13 % -- %
Customer 4
1 % 27 %

~~Revenues~~

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended March 31,
	2022			2021			2022			2021
Revenues													2023			2022
Customer 1		36	%		22	%		36	%		15	%		33	%		48	%
Customer 2		14	%		1	%		6	%		1	%		16	%		-
Customer 3		1	%		44	%		14	%		20	%

10.	Subsequent Events

~~On October 25, 2022,~~Subsequent to March 31, 2023, the ~~Company announced~~Investor of the ~~pricing of a public offering (the "Offering") of~~March 2023 private placement exercised an aggregate of 11,783,572 units (the "Units") and 2,892,858 pre-funded units (the "Pre-Funded Units”) for a purchase price of $0.14 per unit, resulting in aggregate gross proceeds of approximately $2,055,000. The Offering closed on October 28, 2022. Each Unit sold in the Offering consisted of ~~one~~ ~~share of the Company's common stock and~~ ~~one~~ ~~common warrant to purchase~~ ~~one~~ ~~share of common stock, and each Pre-Funded Unit consisted of~~ ~~one~~ ~~pre-funded warrant to purchase~~ ~~one~~ ~~share of common stock and~~ ~~one~~ ~~common warrant to purchase~~ ~~one~~ share of common stock. The common warrants will be exercisable at an exercise price of $0.14 per share beginning on the effective date of Company stockholder approval of the issuance of the shares upon exercise of the warrants (the "Warrant Stockholder Approval”) and will expire on the ~~fifth~~ ~~anniversary of the effective date of the Warrant Stockholder Approval. The 2,892,858~~368,429 pre-funded warrants ~~sold in the Offering were exercised on October 25, 2022.~~leaving a balance of 578,000 pre-funded outstanding and available for exercise.

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward‑Looking Statements

This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet U.S. Food and Drug Administration (“FDA”) regulated requirements governing the Company’s products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, uncertainty associated with the COVID-19 pandemic, risks associated with expanding into the Company’s planned CDMO business, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission (“SEC”), including, in particular, those set forth in the Company’s Form 10-K for the year ended December 31, ~~2021.~~2022.

Business Overview

ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA.

Our business involves the manufacturing and related service of cell based medical devices, including the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and ~~CAR-TXpress™~~CAR-TXpress platform for large scale cell manufacturing services. The Company and its subsidiaries currently manufacture and market the following products:

Clinical Bio-Banking Applications:

●

AXP®IIAutomated Cell Separation System – an automated, fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510(k) medical device.

●

BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510(k) medical device.

Point-of-Care Applications:

●

PXP®Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics, registered as a U.S. FDA 510(k) medical device.

Table of Contents

●

PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, ~~supernatant~~supernatnt or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510(k) medical device.

●

PXP-1000 System – an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination, registered as a U.S. FDA 510(k) medical device.

Large Scale Cell Processing and Biomanufacturing:

●

X-Series® Products for general laboratory use: X-Lab® for cell isolation, X-Wash® System for cell washing and reformulation, X-Mini® for high efficiency small scale cell purification, and X-BACS® System under development for large scale cell purification using our proprietary Buoyancy-Activated Cell Sorting (“BACS”) technology.

●

~~CAR-TXpress™~~CAR-TXpress Platform for Clinical Manufacturing – a modular designed, functionally closed manufacturing platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing cellular therapies, including chimeric antigen receptor (“CAR”) T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest.

~~Planned~~ Expansion of Business – Contract Development and Manufacturing Services for Cell and Cell-Based Gene Therapies

~~In March 2022, our Board of Directors approved the planned expansion of the Company’s~~The Company expanded its business to include contract development and manufacturing services for cell and cell-based gene therapies. The Company ~~plans to develop and build-out~~is in the process of building out the capabilities to become a world-class ~~CDMO~~Contract Development and Manufacturing Organization (“CDMO”) for cell and cell-based gene therapies by partnering with Boyalife Genomics Tianjin Ltd., a China-based CDMO (“Boyalife Genomics”), to in-license certain know-how and other intellectual property from Boyalife Genomics, and by leasing and buildingtherapies. The Company is rolling out a ~~cell manufacturing~~new facility in the Sacramento ~~California.~~metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy companies. The ReadyStart Suites are located in a 35,500+ square foot cGMP facility that will meet the highest scientific, quality, and regulatory requirements. We intend to leverage our existing technology and combine it with the in-licensed technologies to develop a proprietary manufacturing platform for cell manufacturing activities.

The Company plans to develop and operate its planned CDMO business through a newly formed division named TG Biosynthesis^TM. It is anticipated that TG Biosynthesis will provide high-quality development and manufacturing capabilities, cell and tissue processing development, quality systems, regulatory compliance, and other cell manufacturing solutions for clients with therapeutic candidates in various stages of development.

We ~~are targeting~~expect the ~~launch of our~~ CDMO ~~services~~facility to ~~customers~~be completed in 2023. The successful development and launch of TG Biosynthesis will require us to raise additional capital, acquire various equipment for the planned operations, hire certain personnel needed to launch the operation, and timely complete the build-out of our leased Sacramento facility. There is no assurance that we will be able to successfully obtain such additional capital resources, as such capital may not be available on reasonable terms, or available at all. We will need to hire, train, and retain additional employees who have experience in the cell manufacturing field in order for our CDMO business to be successful.

Table of Contents

Results of Operations

Three Months Ended ~~September 30, 2022~~March 31, 2023 as Compared to the Three Months Ended ~~September 30, 2021~~March 31, 2022

Net Revenues

Net revenues decreased by ~~$1,043,000~~$91,000 or ~~33%~~3%, from ~~$3,158,000~~$2,663,000 to ~~$2,115,000~~$2,572,000 for the three months ended ~~September 30, 2022~~March 31, 2023 as compared to the three months ended ~~September 30, 2021.~~March 31, 2022. The decrease in revenue ~~decrease~~ was ~~due to $1,201,000 in lower sales for AXP~~ driven by ~~approximately $1,300,000 less~~lower AXP disposable sales to ~~our~~the Company’s international distributors ~~in China~~and CAR-TXpress sales, which were offset by ~~$95,000 more in~~increased BioArchive service revenue and manual disposable ~~sales.~~sales for the quarter ended March 31, 2023.

The following table summarizes revenue by product line:

	September 30, 2022		September 30, 2021		March 31, 2023		March 31, 2022
AXP	$	1,109,000	$	2,310,000	$	1,539,000	$	1,766,000
BioArchive		522,000		518,000		657,000		453,000
CAR-TXpress		306,000		262,000		146,000		313,000
Manual Disposables		150,000		55,000		207,000		105,000
Other		28,000		13,000		23,000		26,000
Total	$	2,115,000	$	3,158,000	$	2,572,000	$	2,663,000

Gross Profit

The Company’s gross profit ~~decreased~~increased by ~~$678,000~~$165,000 to ~~$437,000~~$1,105,000 or ~~21%~~43% of net revenues for the three months ended ~~September 30, 2022,~~March 31, 2023, compared to ~~$1,115,000~~$940,000 or 35% for three months ended ~~September 30, 2021.~~March 31, 2022. The primary driver of the ~~decrease~~increase was lower inventory reserves in the ~~decline~~quarter ended March 31, 2023 as compared to the same period last year. In the first quarter of last year, the Company incurred approximately $300,000 in ~~revenues, which reduced gross profit by approximately $300,000. The remainder of the variance is~~additional inventory reserve expenses driven by ~~higher costs from our AXP disposable contract manufacturer of approximately $100,000 and increased overhead charges of approximately $275,000 due to lower absorption~~reserves for obsolete BioArchive parts, with no additional material inventory reserves in the ~~three months ended September 30, 2022.~~first quarter of 2023.

Selling, General and Administrative

Sales, general and administrative expenses for the three months ended ~~September 30, 2022~~March 31, 2023 were ~~$1,982,000~~$1,844,000 compared to ~~$1,677,000~~$1,693,000 for the three months ended ~~September 30, 2021,~~March 31, 2022, an increase of ~~$305,000~~$151,000 or ~~18%~~9%. The increase was driven by rent ~~expense~~and operating expenses for the Company’s CDMO facility of approximately ~~$325,000 for the new CDMO facility leased~~$350,000 and offset by ~~the Company beginning in April 2022.~~lower employee benefit expenses of approximately $150,000.

Research and Development Expenses

Research and development expenses were ~~$470,000~~$306,000 for the three months ended ~~September 30, 2022~~March 31, 2023 as compared to ~~$543,000~~$456,000 for the three months ended ~~September 30, 2021,~~March 31, 2022, a decrease of ~~$73,000~~$150,000 or ~~13%~~33%. The decrease was driven by ~~approximately $80,000 less in salaries~~lower personnel and ~~benefits.~~project expenses.

Interest Expense

Interest expense for the three months ended ~~September 30, 2022~~March 31, 2023 was ~~$1,391,000,~~$3,903,000 compared to ~~$1,530,000,~~$823,000, for the three months ended ~~September 30, 2021, a decrease~~March 31, 2022, an increase of ~~$139,000 or 9%.~~$3,080,000. The ~~decrease is due~~increase was driven by approximately $3,400,000 in additional amortization expenses related to approximately $900,000 less in debt discount from the adoption of ASU 2020-06 and approximately $170,000 in lower interest expense due to the portion of the Boyalife Convertible Promissory Note that was converted in June 2022. This was offset by the down round triggering events ~~of approximately $940,000~~ that occurred ~~in 2022 relating to the Boyalife Convertible Promissory Note.~~

~~Table of Contents~~

~~Other Income / Expense~~

~~Other income decreased~~ in the three months ended ~~September 30, 2022 due to the Employee Retention Tax Credits recorded by the Company in the three months ended September 30, 2021.~~

~~Nine Months Ended September 30, 2022 as Compared to the Nine Months Ended September 30, 2021~~

~~Net Revenues~~

~~Net revenues increased by $931,000 or 14%, from $6,876,000 to $7,807,000~~March 31, 2023 for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021. The revenue increase was driven by additional AXP sales of $1,169,000 related to increased sales from our domestic customers of approximately $1,650,000. The increase is also offset by a decrease in sales $199,000 in BioArchive and $94,000 in CAR-TXpress sales.

~~The following table summarizes revenue by product line:~~

Nine Months Ended September 30,

2022

2021

AXP
$ 4,839,000 $ 3,670,000
BioArchive
1,618,000 1,817,000
CAR-TXpress
911,000 1,005,000
Manual Disposables
357,000 300,000
Other
82,000 84,000
Total
$ 7,807,000 $ 6,876,000

~~Gross Profit~~

~~The~~ Company’s gross profit was $2,316,000 or 30% of net revenues for the nine months ended September 30, 2022, compared to $2,809,000 or 41% of net revenues for the nine months ended September 30, 2021, a decrease of $493,000. The decrease was driven by approximately $300,000 more in inventory reserves and higher costs from our AXP disposable contract manufacturer of approximately $575,000;convertible notes payable, which were offset by approximately ~~$275,000~~$200,000 less in ~~gross profit from additional sales in the nine months ended September 30, 2022.~~

~~Selling, General and Administrative~~

Sales, general and administrative expenses for the nine months ended September 30, 2022 were $5,665,000 compared to $7,171,000 for the nine months ended September 30, 2021, a decrease of $1,506,000 or 21%. The decrease was driven by stock compensation expense, which decreased by approximately $2,050,000 primarily due to the acceleratedinterest expense for the stock options that were voluntarily surrendered by Company executives in the nine months ended September 30, 2021. This was offset by approximately $650,000 for the new CDMO facility leased by the Company beginning in April 2022.

~~Research and Development Expenses~~

Research and development expenses were $1,317,000 for the nine months ended September 30, 2022, compared to $1,544,000 for the nine months ended September 30, 2021, a decrease of $227,000 or 15%. The decrease was driven by approximately $225,000 less in stock compensation expense.

~~Interest Expense~~

Interest expense decreased to $3,572,000 for the nine months ended September 30, 2022 as compared to $4,573,000 for the nine months ended September 30, 2021 a decrease of $1,001,000 or 22%. The decrease is due to approximately $2,700,000 less in debt discount from the adoption of ASU 2020-06 and approximately $170,000 in lower interest expense due to the portion of the Boyalife Convertible Promissory Note that was converted in June 2022. This was offset by the down round triggering events of approximately $1,900,000 that occurred in 2022 relating to the Boyalife Convertible Promissory Note.

1817

Table of Contents

~~Gain on Extinguishment of Debt~~

The Company recorded no gain on the extinguishment of debt in the nine months ended September 30, 2022 as compared to a gain of $652,000 for the nine months ended September 30, 2021. The gain was related to the principal and accrued interest for the Paycheck Protection Program loan the Company received in 2020 and forgiven in March 2021.

~~Other Income / Expense~~

~~Other income decreased in the nine months ended September 30, 2022 due to the Employee Retention Tax Credits recorded by the Company in the nine months ended September 30, 2021.~~

Liquidity and Capital Resources

~~At September 30, 2022, the~~The Company had cash and cash equivalents of ~~$3,903,000~~$5,854,000 and $4,177,000 and working capital of ~~$515,000. This compares to cash~~$498,000 and ~~cash equivalents of $7,280,000~~$(625,000) at March 31, 2023 and ~~working capital of $8,616,000 at~~ December 31, ~~2021.~~2022, respectively. We have primarily financed cash shortfalls from operations through private and public placement of equity ~~securities~~ and ~~our line~~debt securities.

On March 15, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) pursuant to which the Company agreed to issue and sell to the Investor in a private placement (the “Offering”) (i) 125,000 shares of ~~credit facility.~~its common stock, $0.001 par value (the “Common Shares”), (ii) 946,429 pre-funded warrants to purchase Common Shares at a purchase price of $2.80, and (iii) warrants to purchase up to an aggregate 1,071,429 Common Shares were issued. The warrants have an exercise price of $2.65 per share and are exercisable immediately upon issuance and expire five and one-half years following the issuance for a total net proceeds of approximately $2.6 million, excluding legal and transaction fees. The Offering closed on March 20, 2023.

The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. We anticipate opening our new CDMO facility in 2023 and increasing cash from operations. The Company will likely need to raise additional capital to grow its business, fund operating expenses and make interest ~~payments, as well as to fund its planned expansion into CDMO business.~~payments. The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all. These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report.

We manage the concentration of credit risk with our customers and distributors through a variety of methods including pre-shipment deposits, credit reference checks and credit limits. Although management believes that our customers and distributors are sound and creditworthy, a severe adverse impact on their business operations could have a corresponding material effect on their ability to pay timely and therefore on our net revenues, cash flows and financial condition.

~~Table of Contents~~

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

ThermoGenesis Holdings is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information under this item.

ITEM 4. Controls and Procedures

The Company carried out an evaluation, under the supervision, and with the participation of management, including both the Company’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) or 15d-15(e)) as of ~~September 30, 2022.~~March 31, 2023. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have both concluded that the Company’s disclosure controls and procedures were effective as of ~~September 30, 2022.~~March 31, 2023.

There were no changes in the Company’s internal controls over financial reporting that occurred during the three months ended ~~September 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.

2018

Table of Contents

PART II - OTHER INFORMATION

ITEM 1.Legal Proceedings

~~Legal Proceedings~~

In the normal course of operations, we may have disagreements or disputes with distributors, vendors or employees. Such potential disputes are seen by management as a normal part of business and while the outcome of such disagreements and disputes cannot be predicted with certainty, we do not believe that any pending legal proceedings are material. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

ITEM 1A.Risk Factors

~~Risk Factors~~

There have been no material changes to the risk factors relating to the Company set forth in, “Item IA. Risk Factors” of its Annual Report on Form 10-K ~~other than noted below,~~ for the year ended December 31, ~~2021.~~2022, except as follows:

~~If we are uable to comply with~~Sales of substantial amounts of our Common Stock by the ~~continued listed standard of~~selling stockholders named in the ~~Nasdaq Capital Market Stock Exchange (~~“~~Nasdaq~~”~~), our shares may be delisted; which~~Registration Statements on Form S-3 filed by us in April 2023, or the perception that these sales could occur, could adversely affect the price of our ~~common stock~~Common Stock.

In April 2023, we filed two resale registration statements on Form S-3 for the selling stockholders named therein, and ~~its liquidity.~~ ~~Our common stock is currently listed~~such registration statements were declared effective in April and May 2023, respectively. The sale by the selling stockholders of a significant number of shares of Common Stock could have a material adverse effect on ~~Nasdaq.~~the market price of our Common Stock. In addition, the perception in the public markets that the selling stockholders may sell all or a portion of their shares as a result of the registration of such shares for resale pursuant to this prospectus could also in and of itself have a material adverse effect on the market price of our Common Stock. We ~~must comply with Nasdaq’s continued listing requirements related to, among other things, stockholders’ equity,~~cannot predict the effect, if any, that market ~~value, minimum bid~~sales of those shares of Common Stock or the availability of those shares of Common Stock for sale will have on the market price of our Common Stock.

ITEM 2.Unregistered Sales of Equity Securities and ~~corporate governance~~Use of Proceeds

None, except as previously disclosed in ~~order to remain so listed. There can be no assurances that we will be able to comply~~Form 8-K filed with the ~~applicable listing requirements. As previously noted~~SEC on March 7, 2022, the Company received written notice ("Notification Letter”) from the Nasdaq Listing Qualifications Department ("NASDAQ”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in NASDAQ Listing Rule 5550(a)(2) for continued listing on the Capital Market, due to the bid price of the Company’s common stock closing below the minimum $1 per share for the thirty (30) consecutive business days prior to the date of the Notification Letter. In accordance with listing rules, the Company was afforded 180 days, or until September 5, 2022, to regain compliance. The Company was unable to regain compliance with the bid price requirement by September 5, 2022. However, on September 7, 2022, the Company received a notice from NASDAQ granting the Company an additional 180 calendar days, or until March 6, 2023, to regain compliance with the minimum $1.00 bid price per share requirement for continued listing on the Capital Market. NASDAQ determined that the Company is eligible for the second compliance period due to the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.21, 2023.

~~ITEM 2.~~

ITEM 3.Defaults Upon Senior Securities

~~Unregistered Sales of Equity Securities and Use of Proceeds~~

None.

~~ITEM 3.~~

ITEM 4.Mine Safety Disclosure

~~Defaults Upon Senior Securities~~

~~None.~~

~~ITEM 4.~~

~~Mine Safety Disclosure~~

Not applicable.

ITEM 5.Other Information

~~Other Information~~

None.

2119

Table of Contents

ITEM 6.Exhibits

~~Exhibits~~

Exhibit No.	Description
1.1	At the Market Offering Agreement, dated December 13, 2019, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC, incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 (Registration No. 333-235509) filed on December 13, 2019.
1.2	Amendment No.1 to At the Market Offering Agreement dated May 19, 2020, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC, incorporated by reference to Exhibit 1.1 to Form 8-K filed May 20, 2020.
1.3	Amendment No. 2 to At the Market Offering Agreement dated May 19, 2020, by and between ThermoGenesis Holdings, Inc. and H.C. Wainwright & Co., LLC, incorporated by reference to Exhibit 1.3 to Form 8-K filed February 3, 2022.
3.1	Amended and Restated Certificate of Incorporation of ThermoGenesis Holdings, Inc. dated as of June 5, 2020, as amended December 21, 2022., incorporated by reference to Exhibit 3.1 to Form ~~8-K~~10-K filed ~~June 6, 2020.~~March 30, 2023.
3.2	Amended and Restated Bylaws of ThermoGenesis Holdings, Inc., incorporated by reference to Exhibit 3.2 to Form 8-K filed with the SEC on ~~October 30, 2019.~~March 10, 2023.
~~3.3~~	~~First Amendment to the Amended and Restated Bylaws of ThermoGenesis Holdings, Inc., incorporated by reference to Exhibit 3.1 to Form 8-K filed December 17, 2021.~~
~~3.4~~	~~Second Amendment to Amended and Restated Bylaws of ThermoGenesis Holdings, Inc. dated June 30, 2022, incorporate by reference to Exhibit 3.1 to Form 8-K filed July 6, 2022.~~
4.1	Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 to Form 8-K filed with the SEC on March 28, 2018.
4.2	Form of Common Warrant, incorporated by reference to Exhibit 10.37 of amended Registration Statement on Form S-1 filed with the SEC on May 14, 2018.
4.3	Investors’ Rights Agreement, dated January 1, 2019, among CARTXpress Bio, Inc., Bay City Capital Fund V, L.P., and Bay City Capital Fund V Co-Investment Fund, L.P., incorporated by referenced to Exhibit 10.3 to Form 8-K filed with the SEC on January 4, 2019.
4.4	~~Form~~Description of ~~Convertible Promissory Note, dated~~Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as ~~of July 23, 2019, between ThermoGenesis Holdings, Inc. and Orbrex USA Co., incorporated by reference to Exhibit 4.1 to Form 8-K filed with the SEC on July 29, 2019.~~amended.
4.5	~~Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 10.41 to Amendment No. 1 to Form S-1 filed with the SEC on April 29, 2022).~~
~~4.6~~	Form of Common Warrant (Incorporated by reference to Exhibit 10.40 to Amendment No. 3 to Form S-1 filed with the SEC on October 17, 2022).
~~4.7~~4.6	~~Description~~Form of ~~Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended,~~Common Warrant, incorporated by reference to Exhibit ~~4.8~~4.1 to Form ~~10-K~~8-K filed with the SEC on March ~~24, 2020.~~21, 2023.
4.7	Form of Pre-Funded Warrant, incorporated by reference to 4.2 to Form 8-K filed with the SEC on March 21, 2023.
4.8	Form of Warrant Amendment Agreement, incorporated by reference to 4.3 to Form 8K filed with the SEC on March 21, 2023.
10.1	Amendment No. 3 to Convertible Promissory Note, dated January 31, 2023, between ThermoGenesis Holdings, Inc. and Orbrex (USA) Co Limited, incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on February 6, 2023.
10.2	Amendment No. 3 to First Amended and Restated Revolving Credit Agreement, dated March 6, 2023, between ThermoGenesis Holdings, Inc. and Boyalife Group, Inc., incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on March 10, 2023.
10.3	Amendment No. 2 to Second Amended and Restated Convertible Promissory Note, dated March 6, 2023, between ThermoGenesis Holdings, Inc. and Boyalife Group Inc., incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on March 10, 2023.
10.4	Form of Securities Purchase Agreement, ~~(Incorporated~~incorporated by reference to ~~Exhibit 10.39 to Amendment No. 3~~10.1 to Form ~~S-1~~8-K filed with the SEC on ~~October 17, 2022).~~March 21, 2023.
10.5	Form of Registration Rights Agreement, incorporated by reference to 10.2 to Form 8-K filed with the SEC on March 21, 2023.
31.1	Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its ~~Inline~~ XBRL tags are embedded within the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File ~~(embedded within the~~(formatted as Inline XBRL and contained in Exhibit 101)

Table of Contents

ThermoGenesis Holdings, Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ThermoGenesis Holdings, Inc. (Registrant)


Dated: ~~November 10, 2022~~May 15, 2023		/s/ Xiaochun (Chris) Xu, Ph.D.

	Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer)


Dated: ~~November 10, 2022~~May 15, 2023		/s/ Jeffery Cauble

	Jeffery Cauble Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

2321

	Nine Months Ended September 30, 2022
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,668,000	$	171,000	$	--	$	4,839,000
BioArchive		694,000		924,000		--		1,618,000
CAR-TXpress		551,000		146,000		214,000		911,000
Manual Disposables		357,000		--		--		357,000
Other		59,000		--		23,000		82,000
Total	$	6,329,000	$	1,241,000	$	237,000	$	7,807,000

	Three Months Ended September 30, 2021
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,217,000	$	72,000	$	21,000	$	2,310,000
BioArchive		221,000		297,000		--		518,000
CAR-TXpress		160,000		31,000		71,000		262,000
Manual Disposables		55,000		--		--		55,000
Other		9,000		--		4,000		13,000
Total	$	2,662,000	$	400,000	$	96,000	$	3,158,000

	September 30, 2022			December 31, 2021
Customer 1		49	%		--	%
Customer 2		15	%		28	%
Customer 3		13	%		--	%
Customer 4		1	%		27	%